MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Liver shield: nutrient may prevent chemo side effect in young leukemia patients
Disease control OngoingThis study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. Liver toxicity from the chemotherapy drug asparaginase often forces treatment delays, whic…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 17, 2026 09:21 UTC
-
Last-Resort access to experimental cell therapy for blood cancer patients
Disease control TEMPORARILY_NOT_AVAILABLEThis program gives patients with certain blood cancers access to Orca-T, a cell therapy, only when their prescribed commercial version is out of specification or expired. The goal is to provide treatment when no other option is available, but it is not a cure and requires ongoing…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 17, 2026 09:21 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for people with blood cancers like leukemia or lymphoma. The goal is to see if adding certain drugs after the transplant can prevent complications and improve survival. About 300 adults and children …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated May 17, 2026 09:19 UTC
-
Childhood leukemia maintenance drug trial pulled before starting
Disease control TerminatedThis study was designed to test the safety and best dose of a drug called revumenib in children with certain types of leukemia after they had a stem cell transplant. The goal was to see if revumenib could help prevent the cancer from returning. However, the trial was withdrawn be…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 17, 2026 09:11 UTC
-
New cell therapy aims to make stem cell transplants safer for blood cancer patients
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers (like leukemia) who need a stem cell transplant. Orca-T is made from a donor's cells and includes special immune cells to help prevent a serious side effect called graft-versus-host disease (GVH…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 17, 2026 09:10 UTC
-
New hope for tough leukemia: first human trial of ziftomenib underway
Disease control OngoingThis study tests a new drug called ziftomenib for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial includes about 263 participants and aims to find the safest dose and see if the drug can control the disease. It also looks at ho…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Smart bomb for leukemia: new combo targets tough cancers
Disease control OngoingThis early-phase study tests a new targeted drug (PVEK) combined with standard chemotherapy for adults with aggressive forms of acute myeloid leukemia and related blood cancers. PVEK works like a smart bomb, attaching to cancer cells and delivering chemotherapy directly to them. …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New engineered graft aims to improve stem cell transplants for kids with leukemia
Disease control TerminatedThis study tests a specially engineered donor graft (Orca-Q) in children and young adults with certain blood cancers who need a stem cell transplant. The goal is to see if this graft is safe and helps the new cells take hold. About 40 participants will be enrolled.
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
Which donor is best? major trial seeks answer for kids with blood cancer
Disease control OngoingThis study looks at children, teens, and young adults with acute leukemia or myelodysplastic syndrome who need a stem cell transplant. It compares two donor types: a partially matched family donor versus a fully matched unrelated donor. The goal is to see which option leads to fe…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New cocktail of drugs shows promise against tough leukemia
Disease control OngoingThis early-phase study tests a combination of drugs, including venetoclax, for adults with a specific type of leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The goal is to find the safest dose and see how well the treatment works. About 20 participants will re…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control OngoingThis study tests whether two drugs, venetoclax and azacitidine, can help prevent leukemia from returning in 100 adults who have already had a stem cell transplant. Participants must be between 18 and 75 years old and in remission after transplant. The goal is to see if this combi…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New combo therapy aims to tame tough leukemia with fewer side effects
Disease control OngoingThis study looks at children and teens with a specific type of leukemia called Philadelphia chromosome-positive ALL. It tests whether a targeted drug called imatinib works as well with a milder chemotherapy regimen as it does with a stronger one, but with fewer side effects. The …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 07, 2026 18:43 UTC